Dominick  Colangelo net worth and biography

Dominick Colangelo Biography and Net Worth

President & CEO of Vericel

Nick Colangelo joined Vericel in 2013 with more than twenty years of executive management and corporate development experience in the biopharmaceutical industry, including nearly a decade with Eli Lilly and Company. During his career, he has held a variety of executive positions of increasing responsibility in product development, pharmaceutical operations, sales and marketing, and corporate development. Mr. Colangelo has extensive experience in the acquisition, development, and commercialization of products across a variety of therapeutic areas. During his tenure at Eli Lilly and Company, he held positions as Director of Strategy and Business Development for Lilly’s Diabetes Product Group and also served as a founding Managing Director of Lilly Ventures. Mr. Colangelo received his B.S.B.A. in Accounting, Magna Cum Laude, from the State University of New York at Buffalo and a J.D. degree, with Honors, from the Duke University School of Law.

What is Dominick Colangelo's net worth?

The estimated net worth of Dominick Colangelo is at least $12.07 million as of March 13th, 2025. Mr. Colangelo owns 259,997 shares of Vericel stock worth more than $12,069,061 as of March 26th. This net worth approximation does not reflect any other assets that Mr. Colangelo may own. Additionally, Mr. Colangelo receives an annual salary of $1,540,000.00 as President & CEO at Vericel. Learn More about Dominick Colangelo's net worth.

How old is Dominick Colangelo?

Mr. Colangelo is currently 60 years old. There are 4 older executives and no younger executives at Vericel. Learn More on Dominick Colangelo's age.

What is Dominick Colangelo's salary?

As the President & CEO of Vericel Co., Mr. Colangelo earns $1,540,000.00 per year. Learn More on Dominick Colangelo's salary.

How do I contact Dominick Colangelo?

The corporate mailing address for Mr. Colangelo and other Vericel executives is 64 SIDNEY STREET, CAMBRIDGE MA, 02139. Vericel can also be reached via phone at (617) 588-5555 and via email at ir@vcel.com. Learn More on Dominick Colangelo's contact information.

Has Dominick Colangelo been buying or selling shares of Vericel?

During the past quarter, Dominick Colangelo has sold $1,217,381.76 of Vericel stock. Most recently, Dominick Colangelo sold 26,592 shares of the business's stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $45.78, for a transaction totalling $1,217,381.76. Following the completion of the sale, the chief executive officer now directly owns 259,997 shares of the company's stock, valued at $11,902,662.66. Learn More on Dominick Colangelo's trading history.

Who are Vericel's active insiders?

Vericel's insider roster includes Dominick Colangelo (President & CEO), Sean Flynn (VP), Steven Gilman (Director), Michael Halpin (COO), Jonathan Hopper (Insider), Joseph Mara, Jr. (CFO), Jonathan Siegal (Vice President & Corporate Controller), Paul Wotton (Director), and Robert Zerbe (Chairman & Director). Learn More on Vericel's active insiders.

Are insiders buying or selling shares of Vericel?

During the last year, insiders at the biotechnology company sold shares 19 times. They sold a total of 162,927 shares worth more than $7,824,858.25. The most recent insider tranaction occured on March, 13th when CEO Dominick Colangelo sold 26,592 shares worth more than $1,217,381.76. Insiders at Vericel own 5.2% of the company. Learn More about insider trades at Vericel.

Information on this page was last updated on 3/13/2025.

Dominick Colangelo Insider Trading History at Vericel

See Full Table

Dominick Colangelo Buying and Selling Activity at Vericel

This chart shows Dominick Colangelo's buying and selling at Vericel by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$1.22MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$1M$0$1MTotal Insider BuyingTotal Insider Selling

Vericel Company Overview

Vericel logo
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $46.42
Low: $46.14
High: $47.74

50 Day Range

MA: $53.73
Low: $45.38
High: $61.80

2 Week Range

Now: $46.42
Low: $39.12
High: $63.00

Volume

352,512 shs

Average Volume

370,699 shs

Market Capitalization

$2.32 billion

P/E Ratio

773.80

Dividend Yield

N/A

Beta

1.78